JBZ

Jabez Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative small-molecule therapies for liquid and solid tumors. The company operates under a proprietary '3-S' framework, prioritizing cancer therapeutics that are Seamless (orally available and patient-friendly), Scalable (efficient and low-cost to manufacture), and Synergistic (designed to integrate with existing standards of care). Its lead candidate, JBZ-001 (formerly HOSU-53), is an orally bioavailable, potent, and selective inhibitor of dihydroorotate dehydrogenase (DHODH) that disrupts the de novo pyrimidine biosynthesis pathway essential for cancer cell proliferation. JBZ-001 is currently undergoing Phase 1 clinical evaluation for advanced solid tumors, non-Hodgkin lymphoma, and acute myeloid leukemia. Jabez Biosciences aims to translate high-quality, target-validated academic research into impactful oncology treatments through capital-efficient development pathways.